![James W. Sharpe](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
James W. Sharpe
Plus aucun poste en cours
Profil
James W.
Sharpe was President and Chief Executive Officer of Astralis Ltd.
He received an MBA from the University of Rochester and a BS degree from Union College.
Anciens postes connus de James W. Sharpe
Sociétés | Poste | Fin |
---|---|---|
Astralis Ltd.
![]() Astralis Ltd. BiotechnologyHealth Technology Astralis Ltd. research and develop drugs for the treatment of immune system disorders and skin diseases. The company's initial product is Psoraxine, a protein extract used for the treatment of the skin disease psoriasis. Psoraxine is a synthesized immuno-therapeutic agent, presented in liquid form and is packed in 0.5 mg ampules for intra-muscular injection. The company's second product is for the treatment of leishmaniasis. The company was founded on June 30, 2001 and is headquartered in Fairfield, NJ. | President | 25/01/2006 |
Formation de James W. Sharpe
Rochester Christian University | Masters Business Admin |
Union College (New York) | Undergraduate Degree |
Expériences
Fonctions occupées
Sociétés liées
Entreprise privées | 1 |
---|---|
Astralis Ltd.
![]() Astralis Ltd. BiotechnologyHealth Technology Astralis Ltd. research and develop drugs for the treatment of immune system disorders and skin diseases. The company's initial product is Psoraxine, a protein extract used for the treatment of the skin disease psoriasis. Psoraxine is a synthesized immuno-therapeutic agent, presented in liquid form and is packed in 0.5 mg ampules for intra-muscular injection. The company's second product is for the treatment of leishmaniasis. The company was founded on June 30, 2001 and is headquartered in Fairfield, NJ. | Health Technology |